Macrophage‐Derived Extracellular Vesicles‐Coated Palladium Nanoformulations Modulate Inflammatory and Immune Homeostasis for Targeting Therapy of Ulcerative Colitis

Jiahui Cheng,Yiming Zhang,Liang Ma,Wenxian Du,Qiang Zhang,Rifeng Gao,Xinxin Zhao,Yujie Chen,Lixian Jiang,Xiaoyang Li,Bo Li,Yan Zhou

DOI: https://doi.org/10.1002/advs.202304002

IF: 15.1

2023-10-10

Advanced Science

Abstract:This study reports a novel macrophage‐derived extracellular vesicle‐coated palladium (Pd@M) nanoformulation for the targeted treatment of ulcerative colitis (UC). Pd@M can potently scavenge ROS, remodel the colonic inflammatory and immune microenvironments in vivo, and ultimately improve mucosal barrier function and induce the remission of UC, providing a promising alternative option for clinical application. Ulcerative colitis (UC) is a chronic inflammatory bowel disease mainly involving the colon and rectum, which features recurrent mucosal inflammation. The excessive production of reactive oxygen species (ROS) is a trigger for pathological changes such as cell apoptosis and disordered immune microenvironments, which are crucial for the progression of UC and can be a promising therapeutic target. Nowadays, the development of targeted therapeutic strategies for UC is still in its infancy. Thus, developing effective therapies based on ROS scavenging and elucidating their molecular pathways are urgently needed. Herein, a biomimetic nanoformulation (Pd@M) with cubic palladium (Pd) as the core and macrophage‐derived extracellular vesicles (MEVs) as the shell is synthesized for the treatment of UC. These Pd@M nanoformulations exhibit multienzyme‐like activities for effective ROS scavenging, excellent targeting ability as well as good biocompatibility. It is verified that Pd@M can regulate the polarization state of macrophages by inhibiting glycolysis, and decrease neutrophil infiltration and recruitment. In this way, the colonic inflammatory and immune microenvironment is remodeled, and apoptosis is prevented, ultimately improving colonic mucosal barrier function and alleviating colitis in the mouse model. This finding provides a promising alternative option for the treatment of UC patients.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry

What problem does this paper attempt to address?

The problem this paper attempts to address is the development of an effective method for treating Ulcerative Colitis (UC). UC is a chronic inflammatory bowel disease that primarily affects the colon and rectum, characterized by recurrent mucosal inflammation. Excessive production of Reactive Oxygen Species (ROS) is a trigger for the pathological changes in UC, such as apoptosis and immune microenvironment disorders, which are crucial for the progression of UC, making them promising therapeutic targets.

Currently, targeted therapeutic strategies for UC are still in their early stages. Therefore, it is particularly urgent to develop effective treatments based on ROS scavenging and elucidate their molecular pathways. This paper proposes a biomimetic nanoformulation (Pd@M), with a core of cubic Palladium (Pd) and a shell of Macrophage-Derived Extracellular Vesicles (MEVs). This Pd@M nanoformulation exhibits multiple enzyme-like activities, can effectively scavenge ROS, and has good targeting ability and biocompatibility.

Specifically, the study found that Pd@M can regulate the polarization state of macrophages by inhibiting glycolysis, reducing the infiltration and recruitment of neutrophils. In this way, Pd@M reshapes the inflammatory and immune microenvironment of the colon, prevents apoptosis, ultimately improves the function of the colonic mucosal barrier, and alleviates colitis in a mouse model. This finding provides a promising new option for the treatment of UC patients.